US Stock Market Move | Regencell Bioscience Holdings Ltd. (RGC.US) surged over 16%, but the company currently has no approved products.

On Wednesday, Regencell Bioscience Holdings Ltd. (RGC.US) soared over 16% to $26.70. It is reported that Regencell Bioscience Holdings Ltd. is an early-stage biotechnology company focused on the research and commercialization of traditional Chinese medicine treatments for neurological cognitive disorders and degenerative diseases, specifically ADHD and ASD. In May last year, there were market rumors that Regencell Bioscience Holdings Ltd. announced that its new generation neuroregulatory chip had received FDA clinical trial approval and would collaborate with the top global medical institution, Mayo Clinic, to conduct research on Parkinson's disease treatment. The rumors also mentioned that the neuroregulatory chip technology belongs to the forefront of brain-machine interface field, and the company plans to use this technology to conduct research on Parkinson's disease treatment, targeting the global market of approximately 10 million patients. Since its establishment in 2014, Regencell Bioscience Holdings Ltd. has yet to receive any product approvals, has no products available for sale, and has not generated any product sales revenue. The company previously stated that it does not expect to generate any income until the commercialization of standardized Chinese medicine formula products for ADHD and ASD patients in Hong Kong.